minimal residual disease

Arcellx reported Phase 2 iMMagine‑1 results for its CAR‑T therapy anito‑cel in relapsed/refractory multiple myeloma. Among 117 patients, the overall response rate reached 96% with 74% achieving complete or stringent complete responses; 95% of evaluable patients attained MRD negativity, 83% sustaining it >6 months. Twelve‑month progression‑free and overall survival were 82.1% and 94.0%, respectively, with median PFS/OS not yet reached. Safety was favorable, showing no delayed neurotoxicities. The company reaffirmed a 2026 U.S. launch in partnership with Kite, aiming for broader global rollout.